Sagimet Biosciences Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Cash flows from operating activities · · · · | ||||||
| Net loss | | $(51,038) | | $(45,567) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Accretion of discount on marketable securities, net | | (389) | | (1,253) | ||
| Non-cash operating lease expense | | 151 | | 145 | ||
| Stock-based compensation expense | | 6,449 | | 5,288 | ||
| Write-off of deferred financing costs | | | 230 | | | — |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | (1,830) | | (5) | ||
| Accounts payable, accrued expenses and other current liabilities | | 929 | | (907) | ||
| Operating lease liabilities | | (152) | | (136) | ||
| Net cash used in operating activities | | (45,650) | | (42,435) | ||
| Cash flows from investing activities | | | | | ||
| Purchases of marketable securities | | | (106,864) | | | (108,087) |
| Sales and maturities of marketable securities | | 111,420 | | 46,404 | ||
| Net cash provided by (used in) investing activities | | 4,556 | | (61,683) | ||
| Cash flows from financing activities | | | | | ||
| Proceeds from sale of Series A common stock, net of issuance costs | | | — | | | 105,750 |
| Payment of financing costs | | — | | (1,045) | ||
| Proceeds from exercise of stock options | | | 275 | | | 114 |
| Net cash provided by financing activities | | 275 | | 104,819 | ||
| Net (decrease) increase in cash and cash equivalents | | (40,819) | | 701 | ||
| Cash and cash equivalents at beginning of period | | 75,840 | | 75,139 | ||
| Cash and cash equivalents at end of period | | $35,021 | | $75,840 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Deferred financing costs within accounts payable and accrued expenses | | $9 | | $— | ||
| Right-of-use assets obtained in exchange for operating lease obligations | | $152 | | $149 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.